Epiminder Ltd (Ticker: EPI AU) is an Australian company specializing in medical technology, specifically developing a sub-scalp device for long-term epilepsy monitoring. Epiminder plans to list on the Australian Securities Exchange (ASX) on December 1, 2025, planning to offer 83.3 million shares at AUD 1.50 per share, raising AUD 124.95 (USD 81.69 million).

Epiminder plans to use the IPO proceeds for heightened expenditure requirements, specifically to fund its "Detect" clinical trial in the United States. According to reports, the company was established with technology developed in conjunction with the Bionics Institute and is significantly backed by Cochlear Ltd, which will retain a substantial stake post-listing. The offering, valuing the company at USD 212.49 million, is managed by E&P Financial Group Ltd and Morgans Corp Ltd.